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Abstract
Mammographic screening and prophylactic surgery can potentially reduce
breast cancer risks among mutation carriers of BRCA families. The evalua-
tion of these interventions is usually complicated by the fact that their effects
may change over time and by the presence of competing risks. We propose a
competing risks model that accounts for time-varying interventions and provide
cause-specific penetrance estimates for breast and ovarian cancers in BRCA1
families. A shared frailty model is specified to account for familial residual de-
pendence with an ascertainment correction through affected probands, which
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accounts for competing risks and time-varying covariates (TVCs). Via simula-
tion studies we demonstrate the good performances of our proposed approach
in terms of bias and precision of the estimators of model parameters and cause-
specific penetrances over different levels of familial correlations. We apply our
new approach to 498 BRCA1 mutation carrier families recruited through the
Breast Cancer Family Registry and illustrate the importance of our approach
accounted for both competing risks and TVCs when estimating cause-specific
penetrance of breast cancer. Breast and ovarian cancers; BRCA; Compet-
ing risks; Time-varying covariate; Frailty model; Mammography; Prophylactic
surgery; Penetrance.
1 Introduction
Between 10-15% of all breast cancers (BCs) are caused by a hereditary predisposi-
tion (Aloraifi and others , 2015). Hereditary Breast and Ovarian Cancer syndrome
(HBOC) is an autosomal dominant disease characterized by germline pathogenic mu-
tations in the BRCA1 and BRCA2 genes for the majority of cases. It is the most
common cause of hereditary forms of both breast and ovarian cancer (OC) (Petru-
celli and others , 2010). The overall prevalence of BRCA1/2 mutations is estimated
to be from 1 in 400 to 1 in 800 with a higher prevalence in the Ashkenazi Jewish
population (1 in 40). Estimates of penetrance (cancer risk) for BRCA1/2 mutations
vary considerably (Petrucelli et al., 2010). Previous large meta-analyses reported
mean cumulative BC risks at age 70 of 57% for BRCA1 and 49% for BRCA2 mu-
tation carriers (Chen and Parmigiani, 2007; Kuchenbaecker and others , 2017). The
OC risks were 40% for BRCA1 and 18% for BRCA2 mutation carriers. Mutation
carriers are also at an elevated risk of developing contralateral breast cancer (CBC)
after a previous unilateral BC (Kuchenbaecker and others , 2017). A recent meta-
analysis estimated the 5-year CBC risk at 15% for BRCA1 mutation carriers and 9%
for BRCA2 mutation carriers after a first BC (Molina-Montes and others , 2014). Risk
prediction models can be used to assess these risks in BRCA1/2 mutation positive
families. These statistical models can help health practitioners to guide women who
could benefit from genetic counselling and also in their clinical management, which
currently comprise intensified surveillance for early BC detection using multimodal
imaging techniques or prophylactic surgery such as bilateral mastectomy for the risk
of BC and risk-reducing bilateral salpingo-oophorectomy (rrBSO) for the risk of OC
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(American College of Obstetricians and Gynecologists, 2017).
BC and OC risk prediction models aim at estimating a woman’s absolute risk
of developing cancer either for a fixed horizon or for a woman’s remaining lifetime.
Several risk prediction models have been proposed for HBOC, the most popular being
the Gail model (Gail et al., 1989), the Claus model (Claus and others , 1994) and its
extension eClaus (Narod and others , 1995), BRCAPRO (Mazzola and others , 2014),
BOADICEA (Lee and others , 2014) and the Tyrer-Cuzick (or IBIS) (Tyrer and oth-
ers , 2004). The relative performance of four commonly used models for breast cancer
risk (IBIS, BOADICEA, BRCAPRO and Gail/BCRAT) have been recently validated
(Terry et al., 2019a). These models have a number of limitations. They cannot es-
timate accurately the risks of multiple cancer events (such as BC or OC) within the
same families and usually do not account for death as a competing risk when estimat-
ing BC or OC age-dependent risks. Moreover, risk factors that have time-dependent
effects on cancer risks are usually ignored or considered fixed over the whole study pe-
riod (e.g., hormonal factors, mammographic screening (MS), surgical interventions).
However, assessing how these factors modify a woman’s BC and OC risks and how
their effects vary with a woman’s age (e.g., age at a surgical intervention or age at
which screening is introduced) is critical to guide clinical decisions.
Competing risks models for clustered failure times data have already been pro-
posed by Gorfine and Hsu (2011), which extended the competing risks model of Pren-
tice and others (1978) to incorporate the frailty variables to cause-specific hazards
models for all the causes. In a subsequent paper, Gorfine and others (2014) showed
through a simulation study that naively treating competing risks as independent right
censoring events resulted in non-calibrated predictions of cancer risks, with the ex-
pected number of events overestimated. Recently, we have also proposed a competing
risks approach for clustered family data applicable to successive time-to-event out-
comes (i.e. the first and second cancer event could each have a competing risk event)
(Choi and others , 2017). However, to our knowledge, none of these approaches was
developed to include time varying covariates (TVCs).
In clinical setting, assessing the effect of TVCs is important especially when the
follow-up duration is long. For example, we can consider a binary variable for a
certain treatment occurring at a later period of the follow-up duration. If we code
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this variable as time invariant covariate (TIC), the duration of treatment exposure
becomes much longer than the actual exposure. We lose the information that the sub-
ject was actually absent of its effect for most part of the follow-up period. This type of
TVC is referred to as permanent exposure (PE) (Keown-Stoneman and others , 2018)
as its effect stays constant permanently since the time of the treatment exposure.
Keown-Stoneman and others (2018) proposed the formulation of TVC effect, which
decays over time with the rate parameter referred to as exponential decay (ED). Cox
and Oakes (1984) have an additional parameter that measures the converged effect
of TVC, referred to as Cox and Oaks (CO) type.
In this paper, our goal is to extend our previous competing risks approach (Choi
and others , 2017) to the situation where the cause-specific hazard function for the
main event of interest, BC, can depend on TVCs such as MS or rrBSO. Another
critical extension is to propose an ascertainment correction that specifically accounts
for the fact that the BRCA1 families have been recruited through a proband affected
by either BC or OC before her study entry, or through an unaffected proband. Finally,
in this framework, residual familial correlation not due to the BRCA1 mutation is
modelled through a shared frailty. With our proposed approach, we have BC, OC and
death from other causes as competing events in BRCA1 mutation families. We also
demonstrated a very relevant application of our model to a large series of BRCA1
families, in particular, with an assessment of rrBSO. The possibility that rrBSO
prevents future BC has been the subject of some debate. Terry and others (2019) did
not find an association after accounting for the time-varying nature of the covariate.
There may be some benefit in rrBSO, however women may elect for rrBSO close to
menopause limiting the impact. Here we consider the impact of the timing of rrBSO
in addition to MS through both simulations and applied analyses.
2 Model
2.1 Shared frailty competing risk model with time-varying
covariates
Consider data arising from n independent families, with family f , f = 1, . . . , n, each
family consisting of nf members, i = 1, . . . , nf . For family member i in family f , we
denote by T ofi and Cfi the time to the first event time and the right censoring time,
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respectively, and by δfi ∈ {1, . . . , J} the type of the first observed event among J
competing events and δfi = 0 if right censored. The observed time is then defined as
Tfi = min(T
o
fi
, Cfi). We denote by zfj the shared frailty specific to the event j (j =
1, · · · , J) within family f . To allow covariates to vary over time, let xfi(t) be the
vector of TVCs at time t for individual i in family f and Xfi(t) = {xfi(u); 0 ≤ u < t}
represent the covariate history up to time t. Then the cause-specific hazard function
for event j for individual i from family f conditional on the covariate history Xfi(t)
and cause-specific familial frailty zfj follows a proportional hazards regression model
hfij(t|Xfi(t), zfj) = lim
dt→0
1
dt
P (t ≤ Tfi < t+ dt, δfi = j|Tfi ≥ t,Xfi(t), zfj)
= h0j(t)zfje
βTj Xfi (t), (1)
where h0j(t) is the baseline hazard function and βj is the vector of the covariate
effects related to event j. Assuming that the future values of covariates up to any
time t > u are not affected by the occurrence of any event at time u, we can define
the overall survival function across all competing events conditional on the covariate
history and frailties as
Sfi(t|Xfi(t), zf ) = exp
{
−
J∑
j=1
Hfij(t|Xfi(t), zfj)
}
, (2)
where zf = {zf1 , . . . , zfJ} and Hfij(t|Xfi(t), zfj) =
∫ t
0
h0j(u)zfje
βTj Xfi (u)du is the
cause-specific cumulative hazard function at time t.
Suppose a time varying covariate xfi(t) = 0 at t < tx and 1 at t ≥ tx, where tx
is the time that change in value of covariate occurred. We can describe the effect of
the TVC that changes over time, denoted by m(·), in three different structures: PE,
ED, and CO as follows,
m(Xfi(t)) =

0 if t < tx (PE,ED,CO)
β if t ≥ tx (PE)
β exp
{− η(t− tx)} if t ≥ tx (ED)
β exp
{− η(t− tx)}+ η0 if t ≥ tx (CO) ,
where for time t ≥ tx, the effect of TVC stays at β for PE, whereas it starts to decrease
exponentially with a rate of e−η to 0 for ED or to η0 for CO. The jth cause-specific
hazard and cumulative hazard function with TVC can be written as
hfij(t|Xfi(t), zfj) = h0j(t)zfjexp
{
m(Xfi(t))
}
,
5
Hfij(t|Xfi(t), zfj) =
∫ t
0
h0j(u)zfjexp
{
m(Xfi(u))
}
du,
where calculation details for cause-specific cumulative hazard for PE, ED and CO
models are specified in Web Appendix A.
2.2 Likelihood construction
Let θ = {h0j(.),βj, kj, ηj, η0j, j = 1, . . . , J} be the vector of parameters involved in
the the model, which consists of baseline parameters for specifying baseline hazard
functions, regression coefficient vector βj, ηj and η0j, related to TVC effects, and
frailty parameter kj for each competing event j = 1, ..., J . Then, the likelihood of the
data from n families can be constructed simply by the product of the likelihoods of
all families:
L(θ) =
n∏
f=1
Lf (θ).
Under the shared frailty competing risk model framework, the likelihood for family
f is obtained by integrating over the frailty distribution:
Lf (θ) =
nf∏
i=1
∫ ∞
0
· · ·
∫ ∞
0
{
J∏
j=1
hfij(tfi |Xfi(tfi), zfj)I(δfi=j)
}
×
Sfi(tfi |Xfi(tfi), zf )g(zf1) . . . g(zfJ )dzf1 . . . dzfJ .
To compute the integrals, we utilize Laplace transform φ(·) of the frailty distri-
bution g(zfj) and its dth derivative, φ(·)(d), which have the following expressions
φ(s) =
∫ ∞
0
e−szg(z)dz
φ(s)(d) = (−1)d
∫ ∞
0
zde−szg(z)dz.
With zfj ∼ Gamma(kj, 1kj ), they have closed form expressions:
φ(s) =
(
1 +
s
kj
)−kj
φ(s)(d) = (−1)d (kj + d− 1)!
kj! k
d−1
j
(
1 +
s
kj
)−kj−d
.
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Then the likelihood for family f can be obtained as
Lf (θ) =
∫ ∞
0
· · ·
∫ ∞
0
nf∏
i=1
J∏
j=1
{
zfjhij(tfi |Xfi(tfi))
}I(δfi=j)
×e−
∑J
j=1 zfjHij(tfi |Xfi (tfi )g(zf1) · · · g(zfJ )dzf1 · · · dzfJ
=
nf∏
i=1
J∏
j=1
hij(tfi |Xfi(tfi))I(δfi=j)(−1)−dfjφ(dfj )
{ nf∑
i=1
Hij(tfi |Xfi(tfi))
}
=
nf∏
i=1
J∏
j=1
hij(tfi |Xfi(tfi))I(δfi=j)
(kj + dfj − 1)!
kj! k
dfj−1
j
{
1 +
∑nf
i=1Hij(tfi|Xfi(tfi))
kj
}−kj−dfj
,
(3)
where dfj =
∑nf
i=1 I(δfi = j) is the number of family members affected by event j.
2.3 Ascertainment correction
We correct for the ascertainment bias by implementing prospective likelihood ap-
proach (Choi and others , 2008). Families are ascertained via the probands (indexed
as p) who have at least one of the competing events (BC, OC or death from other
causes) before their age at examination (afp). The reason we also consider death as
an ascertainment event is that in our real application, a small number of probands
were unaffected at study entry but died during the follow-up period.
For each family f , we divide the Lf (θ) by the probability of the proband being
ascertained by her age at examination, Af (θ) = P (Tfp ≤ afp |Xfp(afp)), which can be
derived by
Af (θ) = 1−
∫
· · ·
∫
exp
{
−
J∑
j=1
zfjHfpj(afp |Xfp(afp))
}
?g(zf1) . . . g(zfJ )dzf1 . . . dzfJ
= 1−
J∏
j=1
{
1 +
Hfpj(afp |Xfp(afp))
kj
}−kj
. (4)
In our real data application, we also consider unaffected probands. The ascertain-
ment correction for them is given by
Af (θ) =
J∏
j=1
{
1 +
Hfpj(afp|Xfp(afp))
kj
}−kj
.
Therefore, the ascertainment corrected likelihood for all the families is expressed
as
LC(θ) =
n∏
f=1
Lf (θ)
Af (θ)
.
7
Combining results from (3) and (4), we specify
LC(θ) =
∏n
f=1
∏nf
i=1
∏J
j=1
{
hfij (tfi |Xfi (tfi ))
}I(δfi=j) (kj+dfj−1)!
kj ! k
dfj
−1
j
{
1+
∑nf
i=1
Hfij
(tfi
|Xfi (tfi ))
kj
}−kj−dfj
1−∏Jj=1
{
1+
Hfpj
(afp
|Xfp (afp ))
kj
}−kj ,
and the corresponding log-likelihood to obtain maximum likelihood estimates of the
parameters as
`C(θ) =
n∑
f=1
logLf (θ)−
n∑
f=1
logAf (θ)
=
n∑
f=1
{ nf∑
i=1
J∑
j=1
I(δfi = j)loghfij(tfi |Xfi(tfi))
}
+
n∑
f=1
[ J∑
j=1
log{(kj + dfj − 1)!} − log(kj!)− (dfj − 1)log(kj)
−(kj + dfj)log
{
1 +
∑nf
i=1Hfij(tfi |Xfi(tfi))
kj
}]
−
n∑
f=1
log
[
1−
J∏
j=1
{
1 +
Hfpj(afp|Xfp(afp))
kj
}−kj]
. (5)
2.4 Cause-specific penetrance function with time-varying co-
variates
Our main interest is to estimate the jth cause-specific cumulative incidence function
Fj(·), also called cause-specific penetrance. We first express the conditional cause-
specific penetrance given the random frailty variable zfj as
Ffij(t|Xfi(t), zfj) = P (Tfi ≤ t, δfi = j|Xfi(t), zfj)
=
∫ t
0
hfij(u|Xfi(u), zfj)exp
{
−
J∑
j=1
Hfij(u|Xfi(u), zfj)
}
du.
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Assuming zfj ∼ Gamma(kj, 1kj ) and there are only two competing events, we derive
the marginal cause-specific penetrance from event 1 (j = 1) as follows:
Ffi1(t|Xfi(t)) =
∫ ∞
0
∫ ∞
0
∫ t
0
hfi1(u|Xfi(u), zf1)Sfi(u|Xfi(u), zf1 , zf2)g(zf1)g(zf2)dudzf1dzf2
=
∫ t
0
hfi1(u)(−1)φ(1)
{
Hfi1(u|Xfi(u))
}
φ
{
Hfi2(u|Xfi(u))
}
du
=
∫ t
0
hfi1(u)
(
1 +
Hfi1(u|Xfi(u))
k1
)−k1−1{
1 +
Hfi2(u|Xfi(u))
k2
}−k2
du, (6)
where calculation details for PE, ED and CO models are specified in Web Appendix
B.
2.5 Variance Estimation
The variance-covariance matrix of θˆ is estimated using a robust sandwich variance
estimator,
V (θˆ) = Io(θ)
−1J(θ)Io(θ)−1,
where Io(θ) is the observed information matrix and J(θ) is the expected information
matrix. They can be obtained by
Io(θ) = −∂
2`C(θ)
∂θT∂θ
J(θ) =
∑
f
Uf (θ)U
>
f (θ)
Uf (θ) =
∂logLf (θ)
∂θ
− ∂logAf (θ)
∂θ
.
The variance estimates Vˆ (θˆ) are obtained by evaluating Io(θ) and J(θ) at the
maximum-likelihood estimate θˆ.
The robust variance estimator for the cause-specfic penetrance estimate, Fj(t|θˆ),
is obtained using Delta method:
V (Fj(t|θˆ)) = D>θ (t)V (θˆ)Dθ(t),
where Dθ(t) is the vector of partial derivatives of Fj(t|θˆ) with respect to θ evaluated
at θˆ. The variance estimates Vˆ (Fj(t|θˆ)) are obtained by using Vˆ (θˆ).
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3 Simulation study
3.1 Simulation Study Design
We conducted simulation studies to assess the finite-sample properties of our pro-
posed shared frailty competing risks model. We considered J = 2 competing events
with a TVC affecting a single event. Our simulated datasets mimic BRCA1 mutation
positive families from the Breast Cancer Family Registry (BCFR) used in our appli-
cation with respect to family structure and inclusion criteria. True parameter values
were obtained after fitting our model to the real data. For each dataset, 500 families
were generated under PE, ED and CO TVC models, each with low, medium and high
familial dependence, which corresponds to k1 = 7 (τ = 0.07), k1 = 3.5 (τ = 0.13)
and k1 = 1 (τ = 0.33), respectively, where τ represents a Kendall’s τ . A value close
to 1 indicates higher dependence among the family relatives’ failure times. The pa-
rameter k2 was fixed at the estimated value obtained from the real data analysis. All
combinations of parameters can be found in Table 1. The model included the muta-
tion status as a TIC affecting both events and MS as a TVC for event 1. Detailed
steps of data generation are presented in Web Appendix C. For each scenario, the
model parameters and penetrance estimators are evaluated based on 500 simulations
by comparing bias, empirical standard error (ESE), average standard error (ASE)
and empirical coverage probability (ECP). Bias is defined as the difference between
mean estimate,
¯ˆ
β and the true value of the parameter, β; ESE is obtained by the
standard deviation of the estimates over all simulations,
√∑B
i=1(βˆi − ¯ˆβ)2/(B − 1),
where B = 500 is the number of simulations and βˆi is the parameter estimate from
simulation i, i = 1, . . . , B; ASE is obtained by
∑B
i=1 SE(βˆi)/B, the average of robust
standard errors (SEs) from each simulation. Finally, ECP is the proportion of times
95% confidence interval (CI) defined as βˆi ± Z0.975SE(βˆi) include true value β for
i = 1, . . . , B.
In addition, we also investigated the robustness of the proposed model to misspeci-
fication of the TVC function in our simulations. Bias and efficiency of the misspecified
TVC function are evaluated in comparison to the true TVC model. Simulations re-
sults based on n = 500 families are presented below while Web Tables 1 and 2 include
simulation results for n = 1000 families.
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3.2 Simulation Results
The simulation results for the model parameter estimates are summarized in Ta-
ble 1. Biases of the parameter estimates related to the baseline hazard function
(ρ1, λ1, ρ2, λ2) and regression coefficients (β1screen, β1gene, β2gene) are negligible across
all the TVC models and the levels of familial dependences. ASEs and ESEs are very
close to each other and ECPs are within acceptable range, i.e., between 0.93 and
0.97. The frailty parameter estimates are more biased especially for event 2 and their
ECP is lower than the nominal level, 0.95 (ranged between 0.80 and 0.90). We also
observed that ASEs tend to be larger than ESEs in the CO model. Coverage prob-
ability for k1 was better than for k2 and the bias decreases with the level of familial
dependence.
Table 2 summarizes the simulation results related to the penetrance estimators.
While frailty parameter estimators suffer from bias, penetrance estimators by age
70 for both event 1, F1(70;X), and event 2, F2(70;X), performed well. The bias
was negligible (< 1%) and the ECPs were close to the 0.95 nominal level and within
acceptable range (between 0.93 and 0.97) regardless of the level of familial dependence.
ASEs and ESEs agree with each other in PE model but ASEs tend to be slightly higher
than ESEs in the ED and CO models.
Additional simulations were conducted to evaluate the robustness of the proposed
model to misspecification of the TVC function. We generated datasets under each
TVC model assumption considering a medium familial dependence level (k1 = 3.5)
and then fitting the wrong TVC models to them. Web Tables 3 and 4 summarize
the simulation results for penetrance estimates under TVC misspecification. As ex-
pected, fitting ED and CO models on the dataset generated under a PE TVC leads to
minimal biases. However, we note that screening coefficient β1screen is largely biased
under the CO model. Web Table 3 shows the screening effect β1screen is underesti-
mated while η0 is overestimated. The overall effect on penetrance is however unbiased
since the bias on these two parameters is in opposite direction. Fitting a CO model
on ED-generated data does not result in any bias. In other situations where a sim-
pler TVC model is fitted to more complex true TVC models, substantial biases are
observed for the screened individuals. Therefore, in practice, it is necessary to fit all
three models and select the best model according to the lowest AIC values. In our
simulations we note that the correct model is selected about 88% of the time with this
selection criteria. In Web Tables 1 and 2, we present additional simulation results for
parameter and penetrance estimators for a larger number of families n = 1000. In
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brief, when n = 1000 the bias is substantially lower for all parameters, especially the
frailty parameters, and their ECPs greatly improve (0.88 ∼ 0.93 for k2). Similarly,
penetrance estimators are less biased, i.e. less than 0.1%.
4 Application to BRCA1 Families from BCFR
4.1 Data
Our analyses focus on BRCA1 positive families recruited through the BCFR. The
BCFR (John and others , 2004) was established in 1995 with six participating sites
from the USA, Australia and Canada including Ontario Cancer Care. The BCFR
enrolled most of the families from 1996 to 2000 while continuing to recruit additional
families satisfying its criteria. Families were included whenever they segregate BRCA1
or BRCA2 mutations, exhibit multiple cases of breast or ovarian cancer, are Ashkenazi
Jewish ancestry or from specific racial and ethnic groups. For the population-based
families, each family includes the proband, i.e. the initial member of the family to be
identified, as well as the first and the second degree relatives. The data have extensive
information on the family members including the ages of the breast/ovarian cancer
diagnosis, study entry, surgeries, and mammographic screening as well as mutation
status in BRCA1/2 gene. We restricted our data analyses to the BRCA1 families
in the BCFR, which were identified from 498 probands including a total of 2,650
individuals. The descriptive statistics of the data are summarized in Table 3.
4.2 Analyses
The first primary BC is our event of interest and the first primary OC and death
from other causes than BC or OC are the competing events in our analyses. Age was
considered as the time scale, i.e. age at diagnosis for women with cancer (BC or OC),
and age at last follow-up or death for women without a first BC or OC. We considered
two TVCs in our the analysis: age at MS and age at rrBSO. Prophylactic bilateral
mastectomy was considered as a censoring variable for BC. For MS, we considered
up to three possible screening events. We only accounted for screening and surgery
histories before any events of interest (BC, OC, death or censored). When the age
at rrBSO was less than one year from the age at BC onset, we considered that both
events occurred at the same time and thus rrBSO did not affect BC (n = 12). The
proportion of individuals with OC as first cancer is much lower than that of BC (6.9%
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vs. 34.9%). The proportion of subjects who underwent rrBSO among the BC cohort
is 3% and at least one MS is 21.9%.
4.3 Selection of the TVC models
For both the MS and rrBSO variables, we used the AIC to select the best TVC model
and evaluated the three models, i.e. PE, ED and CO, for each of them. The best
model corresponds to the CO model for both the MS and rrBSO variables with an
AIC of 19080.76 (Web Table 5). In this model, rrBSO and the 3 MSs were highly
significant (p < 0.005) based on the likelihood ratio test when comparing a model
with rrBSO vs. no rrBSO (the 3 MSs included) and a model with the 3 MSs vs. no
MS (rrBSO included), respectively. The description of the following results are based
on this model. The form of the hazard function corresponding the best model and
that of other TVC models are displayed in Web Figure 1. All the TVC models show a
monotonous increase of the hazard with age but the ED and CO models both depict
a sharp peak of the hazard at the age at MS or rrBSO.
4.4 Relative Risk of the BC and OC
The log relative risks associated with the BRCA1 mutation status, MSs, and rrBSO
are presented in Table 4. The log relative risk of mutation status on BC is β1gene =
2.26 (SE = 0.13), which indicates that being a mutation carrier increases the cause-
specific hazard for BC by approximately 9.54 times compared to non-carriers after
adjustment for the three MSs, rrBSO and the residual familial correlation. The log
relative risk of rrBSO on BC is β1rrBSO = −4.75 (SE = 1.46), which decreases the
cause-specific hazard for BC rapidly at the time of rrBSO but this effect dramatically
increases to η0rrBSO = −0.45 (SE = 0.24) with time. The MSs drastically increase
the BC-specific hazard with associated log relative risks for first, second and third
MS of β1screen1 = 3.40 (SE = 0.27), β1screen2 = 3.87 (SE = 0.51), β1screen3 = 3.79 (SE
= 0.92), respectively. Their effects decrease with time to η0screen1 = 0.30 (SE = 0.15),
η0screen2 = −0.59 (SE = 0.47), η0screen3 = −0.24 (SE = 0.50) for the first, second,
third MS, respectively.
There is a positive association between BRCA1 mutation and the cause-specific
hazard of developing OC, where being a mutation carrier increases the cause-specific
hazard by approximately 4.41 times compared to non-carriers. The estimates of
frailty parameters k1 and k2 are 3.15 (95% CI between 2.11 and 4.70) and 0.70 (95%
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CI between 0.33 and 1.52). They correspond to Kendall’s τ around 0.14 for BC and
0.42 for OC.
4.5 Cause-specific penetrance estimation.
Cause-specific penetrance estimates were obtained from the competing-risks model.
When no TVCs are present, i.e., for women without MS and rrBSO, the penetrance
estimate by age 70 is 61.5% (95% CI = (56.7, 66.0)%) for BC, 12.0% (95% CI =
(9.6, 15.0)%) for OC, and 11.7% (95% CI = (9.5, 14.6)%) for death among gene
carriers. The relative contribution of each cancer event and death to the overall
cumulative penetrance by age among mutation carriers is presented in Web Figure
2. The BC-specific penetrance estimates with respect to MS are displayed in Figure
1. The cumulative penetrance of BC by age 70 is 69.8% (95% CI = (62.5, 75.8)%),
59.9% (95% CI = (43.4, 77.4)%) and 57.3% (95% CI = (39.7, 79.3)%) for a woman
having 1,2 and 3 MSs, where the MS occurred at 35, 40 and 45 years, respectively.
The BC-specific penetrance estimate with respect to rrBSO is displayed in Figure 2,
where the left plot is derived from the competing-risks model and the right plot from
a non competing-risks model (i.e. BC as single event). Under the competing-risks
model, for a woman having rrBSO at 40 years or 50 years, the penetrance of BC
by age 70 is 50.2% (95% CI = (40.0, 60.3)%) and 53.4% (95% CI = (46.2, 60.7)%),
respectively. Under a non-competing-risks model, these estimates are 59.0% (95% CI
= (45.5, 72.3)%) and 60.7% (95% CI = (50.6, 71.1)%), respectively.
5 Discussion
Members of BRCA mutation positive families are exposed to a very high risk of
developing BC or OC as first cancer and the risk of BC is likely to depend on time-
varying covariates such as MS and rrBSO in a complex manner. Most risk prediction
models developed for these families do not account for competing risks nor for time-
varying effects on BC. In this paper, we developed a flexible approach based on frailty
models for modelling competing risks (BC, OC or death) in family data, where the risk
of the first competing event (BC) could depend on time-varying covariates. Our model
provides cause-specific cumulative incidence function that estimates age-specific risks
of BC and OC with respect to fixed and time-varying covariates, accounting for
14
death as a competing event and residual familial correlation not due to the mutation
segregating within the family.
Our simulation studies demonstrate the good performances of our approach in
terms of bias and precision of the estimators of model parameters and cause-specific
penetrances over different levels of familial correlations. The frailty-related parameter
estimators had larger biases than other parameter estimators but these biases did not
results in any biases of the cause-specific penetrances. This is a very important result
since the cause-specific penetrance is used by genetic counsellors to guide clinical
decisions such as prophylactic surgery or intensive screening for known mutation
carriers or the decision to have genetic testing for unknown mutation carriers in
BRCA families. Another important result is that, applying models with the wrong
TVC function could also result in substantial biases of the parameter estimators
when fitting a simpler model to a more complex time-varying function. It is therefore
critical to select the correct TVC function to obtain accurate cause-specific penetrance
estimates.
Our application to 498 BRCA1 mutation positive families from the BCFR illus-
trates the importance of accounting for both competing risks and TVCs when esti-
mating cause-specific penetrance of BC among mutation carriers. This penetrance is
clearly modified by interventions such as rrBSO and multiple MSs over a woman’s
lifetime and our new model, which integrates these interventions, might help better
evaluating their long-term and age-specific effects in BRCA families. For instance, we
found that the cumulative BC risk by age 70 was 61.5% for a mutation carrier woman
who did not have rrBSO or any MS. However, for a woman having rrBSO at 40 years
or 50 years and no MS, the penetrance of BC by age 70 drops to 50.2% and 53.4%,
respectively. In our data, there were 14 (0.5%) and 63 (2.4%) of women who had
rrBSO before 40 or 50 years, respectively. Interestingly, under a non-competing risks
model, these estimates are 59.0% and 60.7%, respectively, and lead to the conclusion
that there is no preventive effect of rrBSO on BC. These results with a non-competing
risks model assumption agree with those of Terry and others (2019), which also found
no effect of rrBSO (HR=1.04, 95% CI=0.87-1.24). We also found little cumulative
risk difference in women with rrBSO if they were non-mutation carriers similar to
Terry and others (2019). In addition, with Terry and others (2019), we did find a
decreased risk after rrBSO when using a competing risks model (Figure 2); the differ-
ences were stronger when the earlier rrBSO had occurred. Thus, the main difference
between these two analyses were driven by the assumption of competing risks, which
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we used here, and not assuming a permanent exposure (PE). Our results were similar
to Terry el al. (Web Appendix 6). Other differences between the two studies include
the sample population as we included retrospective BC and OC cases and did not
include data from the kConFab consortium (Terry and others , 2016).
Our model assumes the TVCs as exogenous variables, i.e, the hazard function at
a specific time t is influenced by the observed covariate history up to time t in the
regression model, but the occurrence of BC in [t, t+ dt) is independent of the future
path of the covariate (Cortese and Andersen, 2009). This assumption is realistic for
prophylactic rrBSO and scheduled MS in our application since the observation of
rrBSO and MS does not carry information about the status of BC; however, if the
MS was performed in symptomatic women, the MS may not be completely exogenous
since it could carry information about the status of BC. Even in that latter situation,
our inference is based on the likelihood conditional on the covariate process up to
the time t, so the future path of the covariate would not influence the occurrence of
BC. In the situation where the full path of the TVC is of research interest, e.g. even
after the event of interest, some statistical approaches, such as the joint modeling
of the TVCs as recurrent events and the cancer outcome as a terminal event, could
be proposed. We have recently developed such approach for family data however it
will require further extensions to be applicable to competing risks events (Choi and
others , 2019).
Our model could also help evaluating more intervention options on BC risk, such
as combinations of rrBSO and MSs as well as the ages they could be introduced.
It could be further extended to account for additional competing risks events, e.g.
prophylactic mastectomy, and also to estimate the risks of successive cancer events
after a first BC or OC, for example following our previous work (Choi and others ,
2017). Finally, we are planning to incorporate information on polygenic risk score
from known genetic variants (Kuchenbaecker and others , 2017), that could modify
BC and OC risks by incorporating a kinship matrix into the cause-specific model for
BC and/or OC (Lakhal-Chaieb and others , 2018). These future developments should
lead to a more comprehensive risk prediction model applicable to BRCA families as
well as other families with increased genetic risks.
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Table 1: Empirical parameter estimates from the competing risks model with a time
varying covariate (TVC) under low (k1 = 7), medium (k1 = 3.5) and high (k1 = 1)
familial dependence; permanent exposure (PE), exponential decay (ED) or Cox and
Oaks (CO) models are considered for TVC. For each scenario, the mean bias, empirical
standard error (ESE), average standard error (ASE) and estimated 95% coverage
probability (ECP) are obtained from 500 replicates each with n = 500 families.
TVC True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
model value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
PE log(λ1) -4.83 -0.01 0.06 0.06 0.95 -4.83 0.00 0.06 0.06 0.95 -4.83 0.00 0.06 0.06 0.94
log(ρ1) 0.88 0.00 0.03 0.03 0.94 0.88 0.00 0.03 0.03 0.93 0.88 0.00 0.03 0.03 0.96
log(λ2) -4.96 -0.01 0.09 0.10 0.95 -4.96 -0.02 0.10 0.10 0.94 -4.96 -0.01 0.09 0.10 0.96
log(ρ2) 1.12 0.00 0.07 0.07 0.95 1.12 0.00 0.07 0.07 0.95 1.12 0.00 0.06 0.07 0.96
β1screen 0.67 0.01 0.11 0.11 0.95 0.67 0.00 0.10 0.11 0.96 0.67 0.00 0.11 0.11 0.96
β1gene 1.95 0.01 0.12 0.12 0.95 1.95 0.01 0.12 0.12 0.96 1.95 0.00 0.12 0.11 0.94
β2gene 1.19 0.03 0.23 0.23 0.96 1.19 0.03 0.24 0.23 0.95 1.19 0.02 0.22 0.24 0.96
log(k1) 1.95 0.24 1.08 0.85 0.92 1.25 0.13 0.69 0.48 0.95 0.00 0.02 0.25 0.25 0.95
log(k2) 1.06 0.62 2.17 1.38 0.80 1.06 0.72 2.20 1.41 0.84 1.06 0.61 2.05 1.46 0.86
ED log(λ1) -4.83 -0.01 0.05 0.06 0.96 -4.83 0.00 0.06 0.06 0.95 -4.83 0.00 0.06 0.06 0.96
log(ρ1) 0.83 0.00 0.03 0.03 0.96 0.83 0.00 0.03 0.03 0.95 0.83 0.00 0.03 0.03 0.96
log(λ2) -4.96 0.00 0.09 0.09 0.95 -4.96 -0.01 0.09 0.09 0.96 -4.96 -0.01 0.09 0.09 0.95
log(ρ2) 1.08 0.00 0.06 0.06 0.95 1.08 0.00 0.06 0.06 0.95 1.08 0.00 0.06 0.06 0.95
β1screen 1.87 0.03 0.25 0.25 0.94 1.87 -0.01 0.25 0.25 0.95 1.87 0.03 0.24 0.24 0.94
β1gene 1.86 0.00 0.12 0.12 0.96 1.86 0.01 0.11 0.12 0.95 1.86 0.01 0.11 0.11 0.94
β2gene 1.22 0.01 0.20 0.21 0.95 1.22 0.03 0.22 0.21 0.96 1.22 0.02 0.21 0.22 0.96
log(k1) 1.95 0.23 0.99 0.88 0.93 1.25 0.08 0.49 0.48 0.97 0.00 0.02 0.23 0.24 0.96
log(k2) 1.18 0.51 2.04 1.18 0.85 1.18 0.53 1.70 1.26 0.84 1.18 0.48 1.47 1.28 0.84
log(η) -1.28 0.02 0.32 0.31 0.94 -1.28 0.00 0.32 0.31 0.94 -1.28 0.03 0.30 0.30 0.94
CO log(λ1) -4.83 0.00 0.05 0.06 0.95 -4.83 0.00 0.05 0.06 0.94 -4.83 0.00 0.05 0.06 0.96
log(ρ1) 0.83 0.00 0.03 0.03 0.94 0.83 0.00 0.03 0.03 0.96 0.83 0.00 0.03 0.03 0.97
log(λ2) -4.96 0.00 0.07 0.09 0.95 -4.96 0.00 0.07 0.09 0.97 -4.96 0.00 0.08 0.09 0.95
log(ρ2) 1.07 0.00 0.05 0.06 0.96 1.07 0.00 0.05 0.06 0.97 1.07 0.00 0.05 0.06 0.96
β1screen 1.52 0.04 0.32 0.42 0.96 1.52 0.04 0.33 0.42 0.94 1.52 0.02 0.32 0.42 0.96
β1gene 2.08 0.01 0.10 0.12 0.94 2.08 0.01 0.10 0.12 0.95 2.08 0.01 0.09 0.11 0.96
β2gene 1.57 0.00 0.17 0.21 0.98 1.57 0.00 0.17 0.21 0.94 1.57 0.01 0.16 0.21 0.97
log(k1) 1.95 0.20 0.74 0.86 0.91 1.25 0.10 0.39 0.46 0.96 0.00 0.02 0.18 0.22 0.97
log(k2) 1.26 0.38 1.15 1.39 0.86 1.26 0.35 0.98 1.40 0.90 1.26 0.36 1.10 1.32 0.87
log(η) -0.18 -0.02 0.50 0.58 0.90 -0.18 0.01 0.50 0.60 0.91 -0.18 -0.03 0.48 0.62 0.91
η0 0.21 -0.02 0.12 0.14 0.95 0.21 -0.01 0.12 0.14 0.96 0.21 -0.02 0.12 0.14 0.95
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Table 2: Empirical penetrance estimates by age 70 for the competing risks model with
a time varying covariate (TVC) under low (k1 = 7), medium (k1 = 3.5) and high (k1 =
1) familial dependence; permanent exposure (PE), exponential decay (ED) or Cox and
Oaks (CO) models are considered for TVC; F1(70;S,G) and F2(70;S,G) are cause-
specific penetrance estimators (%) by age 70 for event 1 and event 2, respectively,
given screening (S) and mutation status (G), and screening time at age 35 if S = 1.
For each scenario, the mean bias, empirical standard error (ESE), average standard
error (ASE) and estimated 95% coverage probability (ECP) are obtained from 500
replicates each with n = 500 families.
TVC True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
model value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
PE F1(70;S = 0, G = 0) 12.56 -0.10 1.38 1.36 0.95 12.45 0.01 1.33 1.40 0.94 11.93 0.07 1.48 1.45 0.94
F1(70;S = 1, G = 0) 21.92 -0.01 2.45 2.45 0.94 21.58 0.02 2.37 2.48 0.95 20.09 0.13 2.49 2.50 0.96
F1(70;S = 0, G = 1) 56.52 -0.33 3.20 3.18 0.94 54.51 0.12 3.39 3.42 0.94 46.80 -0.02 3.84 3.92 0.95
F1(70;S = 1, G = 1) 75.63 -0.23 3.75 3.74 0.94 72.59 0.03 4.08 4.06 0.94 61.08 -0.04 4.61 4.79 0.94
F2(70;S = 0, G = 0) 4.73 -0.08 0.82 0.85 0.94 4.73 -0.08 0.87 0.85 0.93 4.74 -0.05 0.79 0.88 0.95
F2(70;S = 1, G = 0) 4.45 -0.08 0.77 0.80 0.94 4.45 -0.08 0.82 0.80 0.93 4.49 -0.05 0.75 0.83 0.95
F2(70;S = 0, G = 1) 9.68 0.04 1.16 1.15 0.94 9.85 -0.04 1.16 1.18 0.95 10.52 0.02 1.29 1.28 0.95
F2(70;S = 1, G = 1) 7.12 0.01 0.91 0.89 0.94 7.42 -0.04 0.91 0.92 0.95 8.56 0.00 1.04 1.04 0.95
ED F1(70;S = 0, G = 0) 13.55 -0.05 1.39 1.42 0.94 13.42 -0.02 1.41 1.44 0.94 12.82 -0.04 1.47 1.47 0.94
F1(70;S = 1, G = 0) 15.49 0.03 1.64 1.64 0.94 15.32 0.05 1.62 1.66 0.94 14.54 0.00 1.61 1.68 0.97
F1(70;S = 0, G = 1) 55.65 -0.28 2.70 3.07 0.97 53.68 -0.05 3.03 3.27 0.96 46.14 0.12 3.56 3.68 0.96
F1(70;S = 1, G = 1) 60.49 -0.10 2.99 3.33 0.97 58.24 0.10 3.26 3.54 0.97 49.69 0.21 3.67 3.94 0.96
F2(70;S = 0, G = 0) 5.39 0.01 0.90 0.91 0.95 5.39 -0.07 0.86 0.92 0.95 5.41 -0.05 0.85 0.93 0.96
F2(70;S = 1, G = 0) 5.26 0.01 0.87 0.89 0.95 5.26 -0.07 0.83 0.89 0.95 5.28 -0.06 0.83 0.91 0.95
F2(70;S = 0, G = 1) 11.38 0.05 1.18 1.22 0.96 11.57 0.04 1.29 1.24 0.95 12.34 -0.05 1.34 1.35 0.95
F2(70;S = 1, G = 1) 9.97 0.01 1.05 1.09 0.96 10.22 0.01 1.12 1.12 0.95 11.20 -0.07 1.20 1.22 0.95
CO F1(70;S = 0, G = 0) 13.54 0.02 1.36 1.42 0.95 13.41 0.02 1.44 1.43 0.95 12.81 0.08 1.34 1.43 0.96
F1(70;S = 1, G = 0) 16.60 -0.04 2.00 2.03 0.95 16.41 -0.04 2.02 2.03 0.94 15.52 -0.02 1.89 1.99 0.95
F1(70;S = 0, G = 1) 61.12 0.07 2.90 2.93 0.96 58.82 0.25 3.15 3.10 0.94 50.11 0.32 3.32 3.49 0.97
F1(70;S = 1, G = 1) 67.55 -0.15 3.94 3.73 0.93 64.90 0.06 3.80 3.86 0.95 54.88 0.09 3.94 4.09 0.95
F2(70;S = 0, G = 0) 5.53 0.04 0.87 0.93 0.95 5.53 0.05 0.88 0.93 0.95 5.55 -0.02 0.89 0.95 0.95
F2(70;S = 1, G = 0) 5.39 0.03 0.85 0.90 0.95 5.39 0.04 0.85 0.91 0.95 5.42 -0.02 0.87 0.93 0.95
F2(70;S = 0, G = 1) 14.27 -0.06 1.24 1.37 0.98 14.61 -0.02 1.38 1.41 0.94 15.91 -0.08 1.51 1.55 0.95
F2(70;S = 1, G = 1) 12.35 -0.06 1.22 1.28 0.96 12.77 -0.02 1.31 1.32 0.95 14.36 -0.07 1.41 1.45 0.95
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Table 3: Descriptive statistics for BRCA1 positive families.
Breast Cancer Ovarian Cancer Death Unaffected Total
N(%) 924 (34.9%) 182 (6.9%) 958 (36.2%) 586 (22.1%) 2650
N(%) of probands 391 (78.5%) 43 (8.6%) 5 (1.0%) 59 (11.9%) 498
N(%) of probands
at study entry 386 (77.5%) 31 (6.2%) 0 (0%) 81 (16.3%) 498
Event age
mean (SD) 44.2 (12.0) 53.0 (11.5) 70.5 (17.9) 50.9 (16.2) 55.8 (19.1)
min, max 21.0, 86.0 28.0, 89.0 18.5, 102.5 18.1, 95.0 18.1, 102.5
BRCA mutation
Noncarrier 29 (3.1%) 4 (2.2%) 14 (1.5%) 229 (39.1%) 276 (10.4%)
Carrier 483 (52.3%) 55 (30.2%) 16 (1.7%) 192 (32.8%) 746 (28.2%)
Untested 412 (44.6%) 123 (67.6%) 928 (96.9%) 165 (28.2%) 1628 (61.4%)
# of mammographic screening
0 722 (78.1%) 158 (86.8%) 944 (98.5%) 257 (43.9%) 2081 (78.5%)
1 160 (17.3%) 19 (10.4%) 7 (0.7%) 174 (29.7%) 360 (13.6%)
2 31 (3.4%) 4 (2.2%) 3 (0.3%) 63 (10.8%) 101 (3.8%)
3+ 11 (1.2%) 1 (0.5%) 4 (0.4%) 92 (15.7%) 108 (4.1%)
rrBSO 28 (3.0%) 0 (0%) 9 (0.9%) 129 (22.0%) 166 (6.3%)
rrBSO stands for risk-reducing bilateral salpingo-oophorectomy.
SD stands for standard deviation.
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Table 4: Parameter estimates associated with BC in the BRCA1 families from BCFR
based on the model with or without competing risks (OC and death) assuming
CO model for mammography screening and CO for risk reducing bilateral salpingo-
oophorectomy.
Competing risks model No competing risks model
Estimate SE p-value Estimate SE p-value
β1gene 2.255 0.128 0.000 2.218 0.132 0.000
β1screen1 3.399 0.267 0.000 3.374 0.266 0.000
β1screen2 3.870 0.510 0.000 3.843 0.510 0.000
β1screen3 3.790 0.922 0.000 3.956 0.899 0.000
β1rrBSO -4.749 1.464 0.001 -4.029 1.102 0.000
log(ηscreen1) 1.402 0.253 0.000 1.481 0.249 0.000
log(ηscreen2) 0.614 0.379 0.105 0.670 0.388 0.085
log(ηscreen3) 1.632 1.002 0.103 1.675 1.005 0.096
η0screen1 0.303 0.145 0.037 0.290 0.154 0.060
η0screen2 -0.594 0.466 0.202 -0.602 0.470 0.200
η0screen3 -0.240 0.497 0.629 -0.364 0.529 0.492
log(ηrrBSO) 0.131 0.680 0.848 0.194 0.814 0.812
η0rrBSO -0.451 0.238 0.058 -0.334 0.268 0.212
log(k1) 1.148 0.204 0.000 1.074 0.216 0.000
log(k2) 0.866 0.393 0.027
β2gene 1.483 0.229 0.000
β3gene -0.351 0.140 0.012
-loglik 9517.38 3862.46
-loglik0† 9525.00 3866.32
p-value∗ 0.002 0.052
† based on the null model without rrBSO
∗ testing for rrBSO effect comparing to the null model based on
the likelihood ratio test with df = 3
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Figure 1: Breast cancer-specific penetrance estimates for mutation carriers with re-
spect to multiple mammographic screenings (MSs). The red line represents a screened
woman and the blue line a woman not screened. The dashed lines represent the 95%
confidence intervals. The plot on the left displays the penetrance of a woman screened
at 35 years vs. non screened. The centre plot displays the penetrance of a woman
screened at 35 and 40 years vs. non screened. The plot on the right displays the
penetrance of a woman screened at 35, 40 and 45 years vs. non screened.
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Figure 2: Breast cancer-specific penetrance estimates for mutation carriers with re-
spect to rrBSO. The left plot is derived from the competing-risks model and the right
plot from a non-competing-risks model (i.e. BC as a single event). The black line
represents a woman who did not have rrBSO, the green line a woman who had rrBSO
at age 40 years and the blue line a woman who had rrBSO at age 50 years. The
dashed lines represent the 95% confidence intervals.
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Supplementary Materials
Web Appendix A:
Derivation of cumulative hazard function with a
time-varying covariate
For the time varying covariate xfi(t) = 0 at t < tx and 1 at t ≥ tx, where tx is the
time that change in value of time varying covariate occurred. The jth cause-specific
cumulative hazard function with TVC for three TVC models (PE, ED, and CO) can
be specified as
Hfij(t|Xfi(t), zfj)=
∫ t
0
h0j(u)zfjexp
{
m(Xfi(u))
}
du
=

H0j(t)zfj if t < tx (PE,ED,CO)
H0j(tx)zfj +
{
H0j(t)−H0j(tx)
}
zfjexp
(
βj
)
if t ≥ tx (PE)
H0j(tx)zfj +
∫ t
tx
h0j(u)zfjexp
{
βje
−ηj(u−tx)}du if t ≥ tx (ED)
H0j(tx)zfj +
∫ t
tx
h0j(u)zfjexp
{
βje
−ηj(u−tx) + η0j
}
du if t ≥ tx (CO)
where H0j(t) =
∫ t
0
h0j(u)du and numerical integration is required for computing cu-
mulative hazard for ED and CO since no closed form exists.
26
Web Appendix B:
Derivation of cause-specific penetrance function with
a time-varying covariate
Similarly, with the time varying covariate xfi(t) = 0 at t < tx and 1 at t ≥ tx, the
marginal cause-specific panetrance function (eq. 6) for the event of interest (j = 1)
becomes: if if t < tx regardless of TVC models,
Ffi1(t|Xfi(t)) =
∫ t
0
h01(u)
{
1 +
H01(u)
k1
}−k1−1{
1 +
H02(u)
k2
}−k2
du,
and if t ≥ tx, it follows respectively under PE, ED and CO models as:
Ffi1(t|Xfi(t)) =
∫ t
0
h01(u)exp(β1)
×
[
1 +
H01(tx) + {H01(u)−H01(tx)}exp(β1)
k1
]−k1−1
×
[
1 +
H02(tx) + {H02(u)−H02(tx)}exp(β2)
k2
]−k2
du, (PE)
Ffi1(t|Xfi(t)) =
∫ t
0
h01(u)exp
{
β1e
−η1(u−tx)}
×
[
1 +
H01(tx) +
∫ u
tx
h01(s)exp
{
β1e
−η1(s−tx)}ds
k1
]−k1−1
×
[
1 +
H02(tx) +
∫ u
tx
h02(s)exp
{
β2e
−η2(s−tx)}ds
k2
]−k2
du, (ED)
Ffi1(t|Xfi(t)) =
∫ t
0
h01(u)exp
{
β1e
−η1(u−tx) + η01
}
×
[
1 +
H01(tx) +
∫ u
tx
h01(s)exp
{
β1e
−η1(s−tx) + η01
}
ds
k1
]−k1−1
×
[
1 +
H02(tx) +
∫ u
tx
h02(s)exp
{
β2e
−η2(s−tx) + η02
}
ds
k2
]−k2
du, (CO)
where β1 and β2 are the cause-specific TVC effect coefficients, η1 and η2 are the cause-
specific TVC decay rate parameters and η01 and η02 are the cause-specific TVC decay
convergence parameters for event 1 and 2, respectively.
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Web Appendix C:
Detailed simulation process
Data were simulated with code modified from the R package ‘FamEvent’ (Choi et al.,
2017). Generation of the cause-specific competing risks survival data is based on the
algorithm proposed by Beyersmann et al. (2009). Data generation and analyses were
performed using R version 3.4.3.
We consider the shared frailty competing risk model with TVC for two competing
risks. For the covariates, we include one TIC and one TVC.
1. G: Binary mutation status TIC. If the individual is a mutation carrier, G takes
value of 1 otherwise 0. We assume cause specific hazards for both competing
events are affected by this variable.
2. X(t): Screening status TVC with the screening time ts. X(t) = 1 if t ≥ ts and 0
otherwise. We assume only the cause-specific hazard for event 1 is affected by
this variable.
The cause-specfic hazards functions for event 1 and event 2 are respectively as
follow:
h1(t|X(t), G, z1) = h01(t)exp{β1geneG+m(X(t))}z1
h2(t|G, z2) = h02(t)exp{β2geneG}z2, (7)
where h01(t) and h02(t) are the Weibull baseline hazard functions, z1 and z2 are
the cause-specfic shared frailties, β1gene and β2gene are the mutation status covariate
coefficients for event 1 and 2, respectively, and m(X(t)) is the effect of the screening
TVC, which takes the following form depending on the model:
m(X(t)) =

0 if t < ts (PE,ED,CO)
βscreen if t ≥ ts (PE)
βscreen exp
{− η(t− ts)} if t ≥ ts (ED)
βscreen exp
{− η(t− ts)}+ η0 if t ≥ ts (CO) .
The algorithm for generating families takes the following three steps based on
model (7). Parameters specified in the data generation process, such as the number
of siblings for each generation in family pedigree and the current age distribution of
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the probands and other family members result in the family structure similar to the
real data in the application section.
Step 1: Family structure
1. For each family, we generate a three-generation pedigree. We fix two members
in the first generation while we generate 2 to 5 siblings in the second and 0 to 2
siblings in the third generations from a truncated negative binomial distribution.
2. Generate the current age of the proband, afp from normal distribution with
mean age of 45 and SD of 10. Then we generate the current ages of other
family members, {af2 , ..., afi} for individual i, i = 2, . . . , nf , from a normal
distribution. The current ages of the first generation are generated with the
mean age equal to afp +20 with SD of 1.5 years. The current ages of the second
generation are generated from mean age equivalent to afp with SD of 1.5 years.
Finally, for the third generation, their current ages are generated with the mean
age subtracted by 20 years from the minimum age of their parents.
3. To generate the screening TVC, we first generate the screening ages ts for all
members of the family from a normal distribution with mean age of 40 and
variance of 2 years. If ts,fi > afi we assume this individual does not experience
screening.
4. Generate shared frailties zf = {zf1 , zf2} for family f for two competing events.
We assume zf1 and zf2 are independent and marginally follow the gamma dis-
tribution with shape parameter k1 and the scale parameter 1/k1 for event 1 and
k2 and 1/k2 for event 2 respectively.
5. Generate the mutation status variable Gfp for the proband assuming all the
probands are the mutation carriers, based on a dominant model with prespeci-
fied BRCA1 mutation allele frequency of 0.0021. Other family members’ muta-
tion statuses are generated conditioning on the proband’s mutation status from
a Bernoulli distribution with a probability of success equal to P (Gfi = 1|Gfp).
This probability depends only on the relationship between the proband and the
ith member of the family by Mendelian inheritance laws.
Step 2: Event times and event types
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1. Generate tfi from the overall survival function: Generate w following a uniform
on [0, 1] and solve for tfi from P (Tfi > tfi |Gfi , ts,fi , zf ) = w.
2. Given tfi , we decide the event type δfi among two competing events using the
rate of the cause-specific hazards at tfi . Compute h1(tfi |Gfi , ts,fi , zf ), h2(tfi |Gfi , ts,fi , zf )
and p = h1
h1+h2
. Run a Bernoulli experiment with the probability of success p.
If success, then δfi = 1 otherwise δfi = 2. If tfi > afi we regard this individual
as censored and δfi = 0. Follow-up duration is defined from age 16 to afi if the
individual is right censored, otherwise it is from age 16 to tfi .
Step 3: Ascertainment condition for the family
1. After generating the event times and types of the family members, keep the
family if it satisfies the condition tfp < afp . This condition mimics the popu-
lation based design of the family studies (Gong and Whittemore, 2003) where
probands are affected before their study entry age, afp .
2. Remove men in the pedigree since the real data only consists of women. Mean
pedigree size of 5 leads to the total number of individuals about 2500 when 500
families are generated, which agrees with BRCA1 data.
To generate the data, we specify the following parameters:
1. baseline hazard function parameters: λ1 and ρ1 for event 1, λ2 and ρ2 for event
2
2. parameters involved in TIC: β1gene and β2gene as genetic effects for each event
3. parameters involved in TVC: βscreen as a screening effect for event 1, η for ED
and CO, additional η0 for CO
4. familial dependence parameter: k1 and k2 for each event
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Web Table 1: Empirical parameter estimates for the competing risks model with
a time varying covariate (TVC) under low (k1 = 7), medium (k1 = 3.5) and high
(k1 = 1) familial dependence; permanent exposure (PE), exponential decay (ED) or
Cox and Oaks (CO) models are considered for TVC. For each scenario, the mean bias,
empirical standard error (ESE), average standard error (ASE) and estimated 95%
coverage probability (ECP) are obtained from 500 replicates each with on n = 1000
families.
TVC True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
model value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
PE log(λ1) -4.83 -0.01 0.04 0.04 0.95 -4.83 0.00 0.04 0.04 0.95 -4.83 0.00 0.04 0.04 0.96
log(ρ1) 0.88 0.00 0.02 0.02 0.96 0.88 0.00 0.02 0.02 0.95 0.88 0.00 0.02 0.02 0.97
log(λ2) -4.96 0.00 0.06 0.07 0.96 -4.96 -0.01 0.07 0.07 0.96 -4.96 0.00 0.07 0.07 0.96
log(ρ2) 1.12 0.00 0.05 0.05 0.95 1.12 0.00 0.05 0.05 0.97 1.12 0.00 0.05 0.05 0.95
β1screen 0.67 0.00 0.08 0.08 0.96 0.67 0.00 0.08 0.08 0.94 0.67 0.00 0.08 0.08 0.94
β1gene 1.95 0.01 0.08 0.08 0.94 1.95 0.00 0.08 0.08 0.94 1.95 0.00 0.08 0.08 0.94
β2gene 1.19 0.00 0.15 0.16 0.97 1.19 0.01 0.16 0.16 0.95 1.19 0.01 0.16 0.17 0.96
log(k1) 1.95 0.12 0.62 0.58 0.95 1.25 0.05 0.36 0.32 0.96 0.00 0.01 0.17 0.18 0.96
log(k2) 1.06 0.48 1.95 0.98 0.88 1.06 0.38 1.38 1.01 0.91 1.06 0.54 2.15 1.00 0.88
ED log(λ1) -4.83 0.00 0.04 0.04 0.95 -4.83 0.00 0.04 0.04 0.95 -4.83 0.00 0.04 0.04 0.95
log(ρ1) 0.83 0.00 0.02 0.02 0.95 0.83 0.00 0.02 0.02 0.95 0.83 0.00 0.02 0.02 0.95
log(λ2) -4.96 -0.01 0.06 0.07 0.96 -4.96 0.00 0.06 0.07 0.96 -4.96 0.00 0.06 0.07 0.98
log(ρ2) 1.08 0.00 0.04 0.05 0.96 1.08 0.00 0.04 0.05 0.96 1.08 0.00 0.04 0.04 0.96
β1screen 1.87 0.01 0.18 0.18 0.94 1.87 0.01 0.16 0.18 0.96 1.87 0.02 0.17 0.17 0.95
β1gene 1.86 0.00 0.08 0.08 0.96 1.86 0.00 0.08 0.08 0.96 1.86 0.01 0.08 0.08 0.96
β2gene 1.22 0.00 0.15 0.15 0.94 1.22 0.02 0.14 0.15 0.97 1.22 0.01 0.15 0.15 0.96
log(k1) 1.95 0.16 0.91 0.59 0.94 1.25 0.04 0.32 0.32 0.95 0.00 0.02 0.16 0.17 0.97
log(k2) 1.18 0.34 1.18 0.92 0.91 1.18 0.36 1.58 0.97 0.90 1.18 0.41 1.37 1.04 0.92
log(η) -1.28 0.01 0.21 0.21 0.95 -1.28 0.00 0.20 0.22 0.96 -1.28 0.03 0.20 0.21 0.96
CO log(λ1) -4.83 0.00 0.03 0.04 0.95 -4.83 0.00 0.03 0.04 0.98 -4.83 0.00 0.03 0.04 0.96
log(ρ1) 0.83 0.00 0.02 0.02 0.95 0.83 0.00 0.02 0.02 0.98 0.83 0.00 0.02 0.02 0.96
log(λ2) -4.96 0.00 0.05 0.06 0.95 -4.96 -0.01 0.05 0.06 0.96 -4.96 0.00 0.05 0.06 0.97
log(ρ2) 1.07 0.00 0.03 0.04 0.97 1.07 0.00 0.03 0.04 0.97 1.07 0.00 0.03 0.04 0.97
β1screen 1.52 0.02 0.26 0.30 0.93 1.52 0.04 0.24 0.31 0.96 1.52 0.04 0.23 0.30 0.96
β1gene 2.08 0.01 0.07 0.08 0.97 2.08 0.01 0.07 0.08 0.95 2.08 0.00 0.07 0.08 0.95
β2gene 1.57 0.00 0.12 0.14 0.95 1.57 0.01 0.11 0.15 0.97 1.57 0.01 0.12 0.15 0.96
log(k1) 1.95 0.03 0.43 0.51 0.94 1.25 0.04 0.25 0.30 0.97 0.00 0.00 0.13 0.16 0.97
log(k2) 1.26 0.27 0.72 0.92 0.93 1.26 0.14 0.71 0.83 0.92 1.26 0.19 0.68 0.87 0.92
log(η) -0.18 0.02 0.35 0.42 0.93 -0.18 0.03 0.33 0.43 0.94 -0.18 0.04 0.36 0.43 0.94
η0 0.21 0.00 0.08 0.09 0.96 0.21 0.00 0.08 0.10 0.97 0.21 -0.01 0.08 0.10 0.96
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Web Table 2: Empirical penetrance estimates by age 70 for the competing risks
model with a time varying covariate (TVC) under low (k1 = 7), medium (k1 =
3.5) and high (k1 = 1) familial dependence; permanent exposure (PE), exponential
decay (ED) or Cox and Oaks (CO) models are considered for TVC; F1(70;S,G) and
F2(70;S,G) are cause-specific penetrance estimators (%) by age 70 for event 1 and
event 2, respectively, given screening (S) and mutation status (G), and screening time
at age 35 if S = 1. For each scenario, the mean bias, empirical standard error (ESE),
average standard error (ASE) and estimated 95% coverage probability (ECP) are
obtained from 500 replicates each n = 1000 families.
TVC True k1 = 7, τ = 0.07 True k1 = 3.5, τ = 0.13 True k1 = 1, τ = 0.33
model value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
PE F1(70;S = 0, G = 0) 12.56 -0.09 0.99 0.97 0.94 12.45 -0.01 1.02 0.98 0.95 11.93 -0.02 0.99 1.02 0.95
F1(70;S = 1, G = 0) 21.92 -0.08 1.78 1.74 0.95 21.58 -0.03 1.79 1.76 0.94 20.09 -0.04 1.73 1.76 0.95
F1(70;S = 0, G = 1) 56.52 -0.09 2.19 2.27 0.96 54.51 0.03 2.41 2.42 0.96 46.80 0.03 2.67 2.77 0.96
F1(70;S = 1, G = 1) 75.63 -0.04 2.57 2.66 0.95 72.59 -0.06 2.84 2.88 0.95 61.08 0.03 3.27 3.38 0.96
F2(70;S = 0, G = 0) 4.73 0.03 0.58 0.61 0.96 4.73 -0.02 0.60 0.61 0.96 4.74 0.00 0.61 0.62 0.94
F2(70;S = 1, G = 0) 4.45 0.02 0.55 0.57 0.95 4.45 -0.02 0.57 0.57 0.95 4.49 0.00 0.58 0.59 0.94
F2(70;S = 0, G = 1) 9.68 0.02 0.80 0.82 0.95 9.85 0.02 0.77 0.83 0.97 10.52 0.01 0.88 0.91 0.96
F2(70;S = 1, G = 1) 7.12 0.00 0.61 0.63 0.96 7.42 0.02 0.62 0.65 0.96 8.56 0.00 0.72 0.73 0.95
ED F1(70;S = 0, G = 0) 13.55 0.01 0.99 1.01 0.96 13.42 0.01 0.96 1.02 0.95 12.82 0.05 1.02 1.04 0.95
F1(70;S = 1, G = 0) 15.49 0.03 1.09 1.16 0.96 15.32 0.06 1.13 1.17 0.95 14.54 0.04 1.15 1.18 0.95
F1(70;S = 0, G = 1) 55.65 -0.10 2.03 2.19 0.98 53.68 -0.08 2.20 2.31 0.96 46.14 0.27 2.53 2.60 0.95
F1(70;S = 1, G = 1) 60.49 -0.05 2.15 2.36 0.97 58.24 0.02 2.42 2.49 0.95 49.69 0.25 2.68 2.78 0.95
F2(70;S = 0, G = 0) 5.39 -0.03 0.60 0.64 0.95 5.39 -0.05 0.61 0.65 0.96 5.41 -0.01 0.62 0.66 0.96
F2(70;S = 1, G = 0) 5.26 -0.03 0.58 0.63 0.95 5.26 -0.05 0.60 0.63 0.95 5.28 -0.01 0.60 0.65 0.96
F2(70;S = 0, G = 1) 11.38 -0.04 0.82 0.86 0.96 11.57 0.04 0.86 0.88 0.96 12.34 0.03 0.98 0.96 0.94
F2(70;S = 1, G = 1) 9.97 -0.04 0.74 0.76 0.96 10.22 0.02 0.77 0.79 0.95 11.20 0.03 0.88 0.87 0.94
CO F1(70;S = 0, G = 0) 13.54 -0.10 0.99 1.00 0.95 13.41 -0.04 0.93 1.01 0.97 12.81 0.01 0.98 1.01 0.96
F1(70;S = 1, G = 0) 16.60 -0.11 1.40 1.43 0.94 16.41 -0.06 1.31 1.43 0.95 15.52 -0.02 1.33 1.40 0.96
F1(70;S = 0, G = 1) 61.12 -0.10 1.93 2.09 0.96 58.82 0.18 2.11 2.19 0.95 50.11 0.05 2.38 2.46 0.95
F1(70;S = 1, G = 1) 67.55 -0.13 2.58 2.65 0.95 64.90 0.11 2.60 2.73 0.95 54.88 -0.04 2.69 2.88 0.96
F2(70;S = 0, G = 0) 5.53 0.02 0.64 0.65 0.95 5.53 -0.06 0.59 0.65 0.96 5.55 0.00 0.63 0.67 0.97
F2(70;S = 1, G = 0) 5.39 0.02 0.62 0.64 0.95 5.39 -0.06 0.58 0.63 0.96 5.42 0.00 0.61 0.65 0.97
F2(70;S = 0, G = 1) 14.27 0.01 0.97 0.97 0.96 14.61 -0.12 0.93 0.99 0.97 15.91 0.02 1.00 1.10 0.97
F2(70;S = 1, G = 1) 12.35 0.01 0.91 0.91 0.94 12.77 -0.11 0.90 0.93 0.94 14.36 0.02 0.94 1.02 0.97
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Web Table 3: Simulation results under a misspecified time varying covariate (TVC):
parameter estimates for the competing risks model with a TVC under low (k1 = 7),
medium (k1 = 3.5) and high (k1 = 1) familial dependence; permanent exposure (PE),
exponential decay (ED) or Cox and Oaks (CO) models are considered as TVC. For
each scenario, the three TVC models are fitted and the mean bias, empirical standard
error (ESE), average standard error (ASE) and estimated 95% coverage probability
(ECP) are obtained from 500 replicates each with n = 500 families.
True Model (PE) Misspecified Model (ED) Misspecified Model (CO)
True True k1 = 3.5, τ = 0.13 True k1 = 3.5, τ = 0.13 True k1 = 3.5, τ = 0.13
TVC value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
PE log(λ1) -4.83 0.00 0.06 0.06 0.95 -4.83 0.01 0.06 0.06 0.95 -4.83 0.00 0.06 0.06 0.95
log(ρ1) 0.88 0.00 0.03 0.03 0.93 0.88 0.00 0.03 0.03 0.95 0.88 0.00 0.03 0.03 0.95
log(λ2) -4.96 -0.02 0.10 0.10 0.94 -4.96 0.00 0.10 0.10 0.95 -4.96 -0.01 0.10 0.10 0.95
log(ρ2) 1.12 0.00 0.07 0.07 0.95 1.12 0.01 0.07 0.07 0.95 1.12 0.00 0.07 0.07 0.95
β1screen 0.67 0.00 0.10 0.11 0.96 0.67 0.05 0.13 0.13 0.93 0.67 -0.30 1.08 0.72 0.54
β1gene 1.95 0.01 0.12 0.12 0.96 1.95 0.00 0.12 0.12 0.95 1.95 0.00 0.12 0.12 0.94
β2gene 1.19 0.03 0.24 0.23 0.95 1.19 0.01 0.23 0.23 0.96 1.19 0.02 0.21 0.23 0.97
log(k1) 1.25 0.13 0.69 0.48 0.95 1.25 0.13 0.58 0.51 0.97 1.25 0.08 0.54 0.50 0.96
log(k2) 1.06 0.72 2.20 1.41 0.84 1.06 0.95 2.49 1.54 0.81 1.06 0.87 2.27 1.57 0.81
η - - - - - 0.00 0.01 0.01 0.01 0.93 0.00 0.02 0.05 0.04 0.91
η0 - - - - - - - - - - 0.00 0.33 1.04 0.72 0.59
True Model (ED) Misspecified Model (PE) Misspecified Model (CO)
ED log(λ1) -4.83 0.00 0.06 0.06 0.95 -4.83 -0.05 0.07 0.06 0.86 -4.83 0.00 0.06 0.06 0.95
log(ρ1) 0.83 0.00 0.03 0.03 0.95 0.83 -0.02 0.03 0.03 0.87 0.83 0.00 0.03 0.03 0.95
log(λ2) -4.96 -0.01 0.09 0.09 0.96 -4.96 0.00 0.10 0.09 0.94 -4.96 -0.01 0.08 0.09 0.96
log(ρ2) 1.08 0.00 0.06 0.06 0.95 1.08 0.01 0.07 0.06 0.94 1.08 0.00 0.06 0.06 0.95
β1screen 1.87 -0.01 0.25 0.25 0.95 1.87 -1.37 0.13 0.13 0.00 1.87 0.04 0.26 0.27 0.96
β1gene 1.86 0.01 0.11 0.12 0.95 1.86 0.04 0.13 0.12 0.95 1.86 0.01 0.11 0.12 0.96
β2gene 1.22 0.03 0.22 0.21 0.96 1.22 0.01 0.23 0.22 0.95 1.22 0.02 0.20 0.21 0.96
log(k1) 1.25 0.08 0.49 0.48 0.97 1.25 0.21 1.08 0.60 0.86 1.25 0.11 0.55 0.49 0.96
log(k2) 1.18 0.53 1.70 1.26 0.84 1.18 0.96 1.72 2.12 0.78 1.18 0.61 1.70 1.46 0.84
η 0.28 0.02 0.09 0.09 0.94 - - - - - 0.28 0.03 0.13 0.11 0.93
η0 - - - - - - - - - - 0.00 -0.02 0.19 0.18 0.95
True Model (CO) Misspecified Model (PE) Misspecified Model (ED)
CO log(λ1) -4.83 0.00 0.05 0.06 0.94 -4.83 -0.02 0.06 0.06 0.94 -4.83 0.03 0.06 0.05 0.90
log(ρ1) 0.83 0.00 0.03 0.03 0.96 0.83 -0.01 0.03 0.03 0.93 0.83 0.01 0.03 0.03 0.94
log(λ2) -4.96 0.00 0.07 0.09 0.97 -4.96 0.01 0.09 0.09 0.92 -4.96 -0.01 0.09 0.09 0.95
log(ρ2) 1.07 0.00 0.05 0.06 0.97 1.07 0.01 0.07 0.06 0.92 1.07 0.00 0.06 0.06 0.94
β1screen 1.52 0.04 0.33 0.42 0.94 1.52 -1.15 0.13 0.12 0.00 1.52 0.10 0.45 0.42 0.88
β1gene 2.08 0.01 0.10 0.12 0.95 2.08 0.02 0.12 0.12 0.94 2.08 0.00 0.12 0.12 0.94
β2gene 1.57 0.00 0.17 0.21 0.94 1.57 0.03 0.24 0.21 0.92 1.57 0.03 0.20 0.21 0.95
log(k1) 1.25 0.10 0.39 0.46 0.96 1.25 0.20 0.82 0.55 0.92 1.25 0.08 0.48 0.44 0.96
log(k2) 1.26 0.35 0.98 1.40 0.90 1.26 0.60 1.39 1.96 0.80 1.26 0.52 1.74 1.38 0.86
η 0.83 0.01 0.59 0.56 0.91 - - - - - 0.83 -0.13 0.51 0.41 0.72
η0 0.21 -0.01 0.12 0.14 0.96 - - - - - - - - - -
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Web Table 4: Simulation results under a misspecified time varying covariate (TVC):
penetrance estimates by age 70 for a competing risks model with a TVC under low
(k1 = 7), medium (k1 = 3.5) and high (k1 = 1) familial dependence; permanent
exposure (PE), exponential decay (ED) or Cox and Oaks (CO) models are considered
for TVC; F1(70;S,G) and F2(70;S,G) are cause-specific penetrance estimators (%)
by age 70 for event 1 and event 2, respectively, given screening (S) and mutation
status (G), and screening time at age 35 if S = 1. For each scenario, the three
TVC models are fitted and the mean bias, empirical standard error (ESE), average
standard error (ASE) and estimated 95% coverage probability (ECP) are obtained
from 500 replicates each with n = 500 families.
True Model (PE) Misspecified Model (ED) Misspecified Model (CO)
True True k1 = 3.5, τ = 0.13 True k1 = 3.5, τ = 0.13 True k1 = 3.5, τ = 0.13
TVC value Bias ESE ASE ECP value Bias ESE ASE ECP value Bias ESE ASE ECP
PE F1(70;S = 0, G = 0) 12.45 0.01 1.33 1.40 0.94 12.45 0.21 1.41 1.43 0.95 12.45 0.01 1.41 1.42 0.96
F1(70;S = 1, G = 0) 21.58 0.02 2.37 2.48 0.95 21.58 -0.35 2.40 2.54 0.95 21.58 -0.14 2.56 2.59 0.95
F1(70;S = 0, G = 1) 54.51 0.12 3.39 3.42 0.94 54.51 0.39 3.30 3.49 0.96 54.51 -0.23 3.30 3.48 0.95
F1(70;S = 1, G = 1) 72.59 0.03 4.08 4.06 0.94 72.59 -0.62 3.97 4.26 0.96 72.59 -0.57 4.05 4.27 0.96
F2(70;S = 0, G = 0) 4.73 -0.08 0.87 0.85 0.93 4.73 0.01 0.88 0.87 0.94 4.73 -0.05 0.81 0.86 0.95
F2(70;S = 1, G = 0) 4.45 -0.08 0.82 0.80 0.93 4.45 0.01 0.83 0.82 0.94 4.45 -0.05 0.77 0.81 0.95
F2(70;S = 0, G = 1) 9.85 -0.04 1.16 1.18 0.95 9.85 -0.04 1.13 1.18 0.94 9.85 0.05 1.05 1.18 0.97
F2(70;S = 1, G = 1) 7.42 -0.04 0.91 0.92 0.95 7.42 -0.01 0.87 0.93 0.96 7.42 0.04 0.84 0.93 0.96
True Model (ED) Misspecified Model (PE) Misspecified Model (CO)
ED F1(70;S = 0, G = 0) 13.42 -0.02 1.41 1.44 0.94 13.42 -0.77 1.63 1.52 0.87 13.42 -0.02 1.39 1.49 0.96
F1(70;S = 1, G = 0) 15.32 0.05 1.62 1.66 0.94 15.32 3.61 2.38 2.29 0.71 15.32 -0.01 1.99 2.01 0.95
F1(70;S = 0, G = 1) 53.68 -0.05 3.03 3.27 0.96 53.68 -1.11 3.79 3.54 0.90 53.68 0.04 3.29 3.39 0.95
F1(70;S = 1, G = 1) 58.24 0.10 3.26 3.54 0.97 58.24 7.37 4.35 4.28 0.61 58.24 -0.03 4.20 4.36 0.96
F2(70;S = 0, G = 0) 5.39 -0.07 0.86 0.92 0.95 5.39 0.07 0.98 0.97 0.94 5.39 -0.05 0.85 0.92 0.95
F2(70;S = 1, G = 0) 5.26 -0.07 0.83 0.89 0.95 5.26 -0.03 0.94 0.93 0.94 5.26 -0.05 0.83 0.90 0.95
F2(70;S = 0, G = 1) 11.57 0.04 1.29 1.24 0.95 11.57 0.20 1.31 1.31 0.95 11.57 0.02 1.16 1.25 0.97
F2(70;S = 1, G = 1) 10.22 0.01 1.12 1.12 0.95 10.22 -0.53 1.08 1.14 0.90 10.22 0.01 1.08 1.16 0.96
True Model (CO) Misspecified Model (PE) Misspecified Model (ED)
CO F1(70;S = 0, G = 0) 13.41 0.02 1.44 1.43 0.95 13.41 -0.29 1.35 1.45 0.94 13.41 0.55 1.50 1.43 0.92
F1(70;S = 1, G = 0) 16.41 -0.04 2.02 2.03 0.94 16.41 1.42 2.17 2.13 0.91 16.41 -1.52 1.67 1.58 0.80
F1(70;S = 0, G = 1) 58.82 0.25 3.15 3.10 0.94 58.82 -0.23 3.19 3.22 0.93 58.82 1.01 3.16 3.06 0.92
F1(70;S = 1, G = 1) 64.90 0.06 3.80 3.86 0.95 64.90 2.70 4.10 3.82 0.85 64.90 -3.31 3.46 3.25 0.81
F2(70;S = 0, G = 0) 5.53 0.05 0.88 0.93 0.95 5.53 0.08 1.02 0.96 0.94 5.53 -0.09 0.89 0.92 0.95
F2(70;S = 1, G = 0) 5.39 0.04 0.85 0.91 0.95 5.39 0.03 0.99 0.93 0.94 5.39 -0.03 0.88 0.91 0.95
F2(70;S = 0, G = 1) 14.61 -0.02 1.38 1.41 0.94 14.61 0.31 1.46 1.48 0.95 14.61 -0.17 1.39 1.39 0.93
F2(70;S = 1, G = 1) 12.77 -0.02 1.31 1.32 0.95 12.77 -0.16 1.35 1.36 0.93 12.77 0.57 1.34 1.35 0.93
34
Web Table 5: Comparison of different TVC competing risks models for modelling MS
and rrBSO variables in the BRCA1 families from the BCFR.
TVC PE for rrBSO ED for rrBSO CO for rrBSO
for screen Estimate Robust SE p-value Estimate Robust SE p-value Estimate Robust SE p-value
PE β1gene 2.196 0.128 0.000 2.247 0.129 0.000 2.245 0.129 0.000
β1screen1 0.864 0.121 0.000 0.847 0.122 0.000 0.866 0.122 0.000
β1screen2 0.904 0.217 0.000 0.818 0.228 0.000 0.869 0.223 0.000
β1screen3 0.702 0.316 0.027 0.437 0.373 0.241 0.498 0.359 0.165
β1rrBSO -0.754 0.204 0.000 -0.947 0.333 0.004 -3.961 1.265 0.002
β2gene 1.365 0.231 0.000 1.429 0.231 0.000 1.474 0.232 0.000
β3gene -0.386 0.143 0.007 -0.375 0.142 0.008 -0.371 0.141 0.009
log(k1) 1.262 0.230 0.000 1.147 0.203 0.000 1.129 0.200 0.000
log(k2) 0.765 0.357 0.032 0.857 0.388 0.027 0.847 0.389 0.030
log(ηrrBSO) -4.231 2.074 0.041 -0.031 0.410 0.939
η0rrBSO -0.649 0.240 0.007
AIC 19299.28 19299.79 19297.05
-loglik 9634.64 9633.90 9631.53
ED β1gene 2.308 0.130 0.000 2.289 0.129 0.000 2.262 0.128 0.000
β1screen1 3.721 0.257 0.000 3.594 0.264 0.000 3.623 0.270 0.000
β1screen2 3.482 0.322 0.000 3.393 0.328 0.000 3.290 0.343 0.000
β1screen3 3.756 0.773 0.000 3.511 0.867 0.000 3.635 0.804 0.000
β1rrBSO -0.566 0.201 0.005 -2.775 1.509 0.066 -4.223 1.073 0.000
β2gene 1.569 0.231 0.000 1.533 0.230 0.000 1.490 0.230 0.000
β3gene -0.316 0.137 0.021 -0.329 0.138 0.017 -0.355 0.140 0.011
log(ηscreen1) 1.334 0.249 0.000 1.284 0.251 0.000 1.234 0.262 0.000
log(ηscreen2) 1.110 0.305 0.000 1.136 0.303 0.000 0.958 0.294 0.001
log(ηscreen3) 1.880 0.692 0.006 1.728 0.728 0.018 1.836 0.701 0.009
log(k1) 1.252 0.230 0.000 1.203 0.222 0.000 1.149 0.204 0.000
log(k2) 0.876 0.388 0.024 0.927 0.438 0.034 0.832 0.382 0.029
log(ηrrBSO) -0.627 0.713 0.379 0.055 0.474 0.908
η0rrBSO -0.442 0.232 0.056
AIC 19084.43 19086.13 19082.56
-loglik 9524.22 9524.07 9521.28
CO β1gene 2.258 0.129 0.000 2.253 0.128 0.000 2.255 0.128 0.000
β1screen1 3.519 0.259 0.000 3.476 0.260 0.000 3.399 0.267 0.000
β1screen2 3.800 0.442 0.000 4.067 0.524 0.000 3.870 0.510 0.000
β1screen3 3.840 0.792 0.000 3.939 0.838 0.000 3.790 0.922 0.000
β1rrBSO -0.568 0.203 0.005 -4.796 2.422 0.048 -4.749 1.464 0.001
β2gene 1.527 0.230 0.000 1.429 0.228 0.000 1.483 0.229 0.000
β3gene -0.347 0.140 0.013 -0.376 0.142 0.008 -0.351 0.140 0.012
log(ηscreen1) 1.470 0.250 0.000 1.461 0.248 0.000 1.402 0.253 0.000
log(ηscreen2) 0.871 0.349 0.012 0.706 0.392 0.071 0.614 0.379 0.105
log(ηscreen3) 1.891 0.748 0.011 1.822 0.826 0.028 1.632 1.002 0.103
η0screen1 0.281 0.146 0.055 0.282 0.145 0.052 0.303 0.145 0.037
η0screen2 -0.348 0.375 0.353 -0.720 0.502 0.151 -0.594 0.466 0.202
η0screen3 -0.010 0.388 0.979 -0.326 0.455 0.473 -0.240 0.497 0.629
log(k1) 1.164 0.209 0.000 1.139 0.205 0.000 1.148 0.204 0.000
log(k2) 1.042 0.465 0.025 0.896 0.410 0.029 0.866 0.393 0.027
log(ηrrBSO) -0.202 0.444 0.648 0.131 0.680 0.848
η0rrBSO -0.451 0.238 0.058
AIC 19082.95 19082.88 19080.76 BEST AIC
-loglik 9520.48 9519.44 9517.38 (p-value∗ = 0.045)
∗ p-value testing for rrBSO effect comparing to PE model based on the likelihood ratio test with df = 2
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Web Figure 1: Hazard functions estimated under the different TVC models in the
BRCA1 families from the BCFR.
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Web Figure 2: Stacked plot of the overall cumulative penetrance estimated from the
competing-risks model and showing the contribution of each competing risk event
(BC, OC and death) by age in the BRCA1 families from the BCFR.
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